AC Immune (NASDAQ: ACIU) — Company Overview, News & Financial Data
AC Immune develops precision therapies for neurodegenerative diseases, focusing on diagnostics and treatments for Alzheimer's and Parkinson's.
AC Immune
AC Immune (NASDAQ:ACIU) is a biopharmaceutical company focused on developing precision therapies for neurodegenerative diseases. Their operations span from research and development to the commercialization of diagnostics and treatments targeting conditions like Alzheimer's disease, Parkinson's disease, and Down syndrome-related disorders. AC Immune's project portfolio includes innovative therapeutic candidates and diagnostic tools aimed at identifying and effectively treating these complex diseases. The company's objective is to advance its pipeline of first-in-class and best-in-class molecules through clinical development, leveraging its proprietary technology platforms to address the significant unmet needs in neurodegenerative care.
Snapshot
Operations
Products and/or services of AC Immune
- Semorinemab, a monoclonal antibody targeting tau protein for Alzheimer's disease treatment.
- ACI-35.030, a vaccine targeting pathological tau protein in Alzheimer's patients.
- ACI-24, an anti-Abeta vaccine for Alzheimer's and Down syndrome.
- Morphomer Tau aggregation inhibitors, aimed at disrupting Tau pathology in neurodegenerative diseases.
- CREAD study, an international, randomized clinical trial on Crenezumab for Alzheimer's.
- PI-2620, a Tau PET tracer for imaging Tau pathology in neurodegenerative diseases.
AC Immune executive team
- Christopher RobertsCFO & VP of Finance
- Piergiorgio DonatiChief Operating Officer
- Martin ZugelInterim CEO & Chairman of the Board
- Gary Anthony WaandersSenior VP of Investor Relations & Corporate Communications
- Matthias MaurerSenior VP & General Counsel
- Oliver SolVP & Head of Clinical Development
- Julien RongereSenior Vice President of Regulatory Affairs & Quality Assurance
- Mark DantonExecutive Vice President of Information Systems & Artificial Intelligence
- Günther StafflerExecutive Vice President of Development
- Francesca CapotostiSenior Vice President of Research
Latest news about AC Immune
AC Immune reports Phase 2 Parkinson’s results
United StatesAC Immune reports positive interim data from ABATE trial of ACI-24
United StatesAC Immune reports breakthrough preliminary data for experimental ALS diagnostic tracer
United StatesAC Immune shares data suggesting Parkinson’s slowdown as firm extends runway to 2027
United States
Key financials
Reported results for AC Immune, in CHF.
- Market cap
- 204.8M
- Revenue (TTM)
- 17.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.5
- Dividend yield
- —
- Profit margin
- -246.5%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 3.6M | -68.9M | -70.4M | |
| 27.3M | -52.4M | -50.9M | |
| 14.8M | -53.6M | -54.2M | |
| 3.9M | -70.8M | -70.8M |